Biology changes before symptoms begin.
SYNC-PREVENT™ is a Clinical Status Monitoring platform built around eleven monitoring layers — laboratory biomarkers, FDA-cleared in-office diagnostics, and physician-reviewed clinical context — for patients 50 and older living with two or more chronic conditions, built to close the gap standard care leaves open.
This is not an RPM dashboard. It keeps the whole patient in front of the physician.
SYNC-PREVENT™ stands for Proactive Risk Evaluation, Vital Early Notification Tracking. The name describes the job: get the earliest signs in front of the physician while the disease is still quiet — before the symptom, before the admission, before the point where reversing it gets hard and expensive. SYNC-PREVENT™ is a clinical execution and coordination platform: it organizes clinical information for physician review, supports physician-directed monitoring programs, and executes physician-established care plans. Remote monitoring and chronic care management are part of the machinery. They are not the idea.
For patients 50 and older, eleven monitoring layers — lab work, in-office device diagnostics, physician-reviewed context, and behavioral follow-through — feed one continuously refreshed view of where each patient's physiology is heading.
The starting point was the American Heart Association's cardiovascular risk model. That model takes a snapshot: traditional risk factors, one moment in time. Synchronize Health built SYNC-PREVENT™ to do what a snapshot can't — follow real physiologic change as it happens, across organ systems, month after month. The platform runs directly and through exclusive regional licensees, including our subsidiary BridgeCare Louisiana.
Most first hospitalizations arrive somewhere around 65 to 70. The fifteen years before that are where the disease builds — quietly. That's the window this platform is pointed at.
Physicians decide. Cleared devices watch. The platform organizes. Synchronize Health is not a medical practice and does not practice medicine — all clinical assessments, decisions, and interventions remain exclusively within the judgment and authority of the treating physician. The SYNC-PREVENT™ platform organizes and transmits patient data to support the physician's independent clinical decision-making, and physician judgment is never displaced by platform outputs. Every escalation exists for one reason: so the physician sees an earlier, fuller picture and decides with better information than standard care gives them.
Six jobs. Each one measurable.
The design targets specific clinical and operational outcomes for physicians, patients, payers, and the teams around them.
Put the pre-symptomatic data in front of the physician — cardiovascular, renal, metabolic, neurologic, and endocrine — territory that score-based and symptom-driven models never reach.
Go past the AHA snapshot with biomarker trends over time, device data, kidney-adjusted context, and data presented across organ systems for the physician's review.
Each core layer sits on an existing CMS billing pathway and plugs into RPM and CCM workflows — advanced monitoring without unfunded services.
Structured screening for CKD, diabetes, hypertension, heart failure, and diabetic eye disease closes the care gaps that quality scores and value-based contracts grade you on.
Physician-defined parameters and structured escalation give the physician a chance to act before the acute event — not a report about it afterward.
TEFCA/Carequality connectivity keeps primary care, specialists, and hospitals reading from the same current chart, so transitions stop dropping information.
Eleven ways of looking. One picture of the patient.
Every layer covers one category of physiologic trouble. Results are presented over time with context assembled for the physician's review — including kidney-function context where it matters — and the physician always sees the underlying results. Measurements organized together give the treating physician a more complete multi-parameter picture of patient status than any single value presented in isolation.
Layers 1–8 run on reimbursable, CMS-aligned lab and device testing. Layers 9–11 are handled separately, with the clinical context they require.
Surfaces the biomarkers of arterial disease while it's still forming — plaque activity, vascular inflammation, and the inherited lipid risk a standard LDL-C misses.
Tracks the biomarkers of subclinical heart failure and kidney decline — including the PTH-driven cardiac pathway that quietly raises HFpEF risk in women past menopause.
Measures insulin resistance years before glucose goes abnormal. Insulin-dependent patients in higher care tiers get a Dexcom G7 feeding this layer continuously.
Watches for fatty liver disease and fibrosis — a silent cardiovascular driver the AHA model never looks at. Velacur elastography confirms when labs raise the question.
Tracks the low-grade inflammatory burden that feeds atherosclerosis, diabetes, and renal disease — plus the nutritional depletion that precedes deterioration.
Surfaces anemia and impaired oxygen transport — under-recognized accelerants of cardiac and cognitive decline — and presents lymphocyte count as a frailty and infection-vulnerability signal for the physician's review.
Device-based testing for dysautonomia — an early warning for sudden cardiac events and diabetic neuropathy that standard vitals never show.
Screens for peripheral artery disease before limb ischemia develops — and for the early microvascular signals of diabetic foot ulcer risk.
Blood-based markers of silent brain injury and cognitive decline risk. Ordered only on physician determination — and always read against kidney function, which independently elevates all three markers.
Motion-based gait analysis that measures the instability that precedes a fall — stride variability, balance, and movement patterns that predate any frailty diagnosis.
Replaces "seems sharp today" with measured memory, attention, processing speed, and executive function — trended visit over visit, corroborating Layer 9's blood markers.
Kidney function changes what every number means.
A biomarker reading in a patient with CKD is not the same reading in a patient with healthy kidneys. Reduced clearance inflates inflammatory markers, vascular injury signals, and neurodegenerative markers alike — and a system that ignores that will misclassify patients, refer them too early, escalate therapy they don't need, and bill for it.
So renal physiology isn't a downstream diagnosis here — it's presented alongside every affected result. Renal-adjusted trend context is assembled for the physician's review, so the physician can separate stable clearance-related elevation from true pathologic progression — with the underlying values always visible.
FDA-cleared devices, run in your clinic, results in minutes.
Each device operates on-site under physician supervision, bills through existing CMS pathways, and feeds its findings straight into the matching monitoring layer — no workflow disruption, no added staff burden.
Reads left ventricular end-diastolic pressure without a catheter — surfacing early heart failure physiology, including HFpEF, that no physical exam can find.
One retinal image, a referral decision in about a minute — the HEDIS diabetic eye exam gap closed without sending the patient anywhere.
Automated ankle- and toe-brachial index. Peripheral artery disease and limb ischemia risk, found before they limit the patient.
HRV, sudomotor function, and autonomic balance — early diabetic neuropathy and cardiovascular instability, caught in a routine visit.
Quantifies hepatic stiffness and steatosis for MASLD/MASH staging — ordered when FIB-4 or Layer 4 labs raise the question.
Synchronize Health supplies the Eko Core 500 AI digital stethoscope to participating physicians for their exclusive independent clinical use. The Eko Core 500 is operated by the physician during their own clinical examination and is not a component of the SYNC-PREVENT™ monitoring platform.
Continuous glycemic trends for insulin-dependent patients in higher care tiers — a moving picture between visits instead of a single fingerstick.
The Bluedrop device identifies plantar temperature asymmetry within its cleared function — a signal of diabetic foot ulcer risk two to four weeks before anything is visible on the skin.
OSA severity, respiratory instability, and desaturation — the sleep apnea quietly feeding AFib, HFpEF, hypertension, and CKD progression.
A raw lab value doesn't tell a physician anything. Context does.
Meaning lives in the surroundings — the medication list, the comorbidities, the trend line, the way findings in one organ system echo in another. The platform presents results with that context organized for the physician's review. It presents evidence, not opinions. It never makes the decision.
Computes the published FIB-4 fibrosis index from age, AST, ALT, and platelets the patient already gave — no extra draw — and presents it with metabolic, cardiac, and renal context for the physician's interpretation. Updated every 6–12 months.
RPM and CCM carry the findings. They aren't the foundation.
Monitoring and chronic care management are how a finding becomes a phone call, an adherence check, a medication reconciliation — the follow-through that turns an insight into an outcome a payer can measure.
Trained coordinators — people, not software — review incoming data against physician-established parameters. What reaches the physician has been reviewed by clinical staff who understand the conditions, the medications, and the escalation pathways — no noise.
Structured escalation pathways connect the care team to the treating physician when collected data falls outside physician-established parameters — not a shared inbox on Monday.
Medication adherence is verified — and reconciled against TEFCA/Carequality data — to cut the medication-driven readmissions and care gaps.
Reports arrive aligned with CMS requirements and ready for signature — the administrative burden goes down, not sideways onto your staff.
A missed reading is a clinical variable, not a nag-reminder trigger. Engagement gaps get structured behavioral intervention under the COM-B framework.
TEFCA/Carequality connectivity gives clinicians the complete patient — not just device readings — with HIPAA-grade data security throughout.
Admissions, discharges, ED visits, abnormal labs, device-detected deterioration — meaningful changes reach the whole care team as they happen, through TEFCA/Carequality connectivity and event-based alerts. When everyone reads the same current chart, transition gaps close, duplicate tests stop, and conflicting treatment decisions become visible before they cause harm.
Measure. Organize. Decide.
FDA-cleared devices and physician-ordered labs capture the data — cardiac, renal, metabolic, neurologic.
The platform assembles results, trends, and history into one picture, with every value visible to the physician.
The treating physician — and only the treating physician — decides. SYNC-PREVENT™ delivers the picture. It never delivers the decision.
SYNC-PREVENT™ isn't built around one disease. It organizes the whole trajectory of deterioration for the physician — before the symptom, before the hospitalization, before the outcome hardens.
This page describes the design of the SYNC-PREVENT™ clinical protocol and is informational only — not medical advice, a diagnosis, or a treatment recommendation. SYNC-PREVENT™ does not interpret clinical data or provide treatment recommendations; the platform collects data from FDA-cleared monitoring devices, organizes it, and transmits it to the treating physician, and all clinical interpretation, assessment, and treatment decisions are made exclusively by the treating physician based on their independent review of the transmitted data. Testing, device use, referrals, and escalations happen solely at the treating physician's direction. Testing frequencies reflect protocol design and may differ per patient. SYNC-PREVENT™ is a trademark of Synchronize Health, LLC.
Close your blind spot.
Thirty minutes. We'll show you what you're missing between visits.
Talk to Our Team